Abstract
Methods Genotypes were determined in an observational cohort of 183 JIA patients that had been systematically followed at 3 months intervals. The following SNPs were determined: methylenetetrahydrofolate reductase (MTHFR) 677C>T and 1298A>C, methionine synthase reductase (MTRR) 66A>G, thymidylate synthase (TS) 2R/3R and Reduced Folate Carrier (RFC) 80G>A. MTX efficacy and adverse effects were compared among genotypes during the first year of treatment and at long-term follow up.
Highlights
Open AccessAddress: 1University Medical Center Utrecht, dept. of pediatric immunology, Utrecht, Netherlands and 2Erasmus Medical Center, Rotterdam, USA * Corresponding author from 15th Paediatric Rheumatology European Society (PreS) Congress London, UK. 14–17 September 2008
Insight into factors associated with outcomes of methotrexate (MTX) treatment may contribute to more individualized treatment of juvenile idiopathic arthritis (JIA)
Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) and MTRR genes are associated with methotrexate efficacy and adverse effects
Summary
Address: 1University Medical Center Utrecht, dept. of pediatric immunology, Utrecht, Netherlands and 2Erasmus Medical Center, Rotterdam, USA * Corresponding author from 15th Paediatric Rheumatology European Society (PreS) Congress London, UK. 14–17 September 2008. Of pediatric immunology, Utrecht, Netherlands and 2Erasmus Medical Center, Rotterdam, USA * Corresponding author from 15th Paediatric Rheumatology European Society (PreS) Congress London, UK. Published: 15 September 2008 Pediatric Rheumatology 2008, 6(Suppl 1):P15 doi:10.1186/1546-0096-6-S1-P15. 15th Paediatric Rheumatology European Society (PreS) Congress Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
